europeanpharmaceuticalreviewJune 21, 2017
First of a series on Brexit guidance
The question-and-answer document contains information around company location in the context of centralised procedures and certain activities, including the location of orphan designation holders, qualified persons for pharmacovigilance (QPPVs), and companies’ manufacturing and batch release sites. EMA is preparing a series of further guidance documents relating to the subject of Brexit that will be published on its website in due course.
From government regulation to European trade, Life Sciences Hub Wales chairperson, Dr Penny Owen, looks ahead to the unknown of a post-Brexit world…
Companies are advised to regularly check EMA’s webpage dedicated to the consequences of Brexit.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: